This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biogen's New Study to Test Higher Dose of SMA Drug Spinraza
by Zacks Equity Research
Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.
Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019
by Zacks Equity Research
Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.
Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.
Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis
by Zacks Equity Research
Roche's (RHHBY) lymphoma drug, Gazyva, obtains Breakthrough Therapy designation in the United States for lupus nephritis.
The Zacks Analyst Blog Highlights: Biogen, Crocs, Casey's General Stores and Clean Harbors
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Crocs, Casey's General Stores and Clean Harbors
Biogen Stops Late-Stage Studies on Alzheimer's Candidate
by Zacks Equity Research
Biogen (BIIB) and its Japanese partner, Eisai receive another setback as they discontinue two late-stage studies evaluating elenbecestat in patients with Alzheimer's disease.
What September Doldrums? Here's Why Stocks Are Moving Higher
by Tirthankar Chakraborty
From ECB stimulus to trade optimism, all are helping stocks eke out gains. And let's admit that recession may be coming, but it isn't around the corner.
Top 5 ROE Stocks to Profit as Sino-US Trade Tensions Abate
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group
by Zacks Equity Research
Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.
5 Price-to-Book Value Picks for September
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Novartis Inks Commercialization Deal for Tysabri Biosimilar
by Zacks Equity Research
Novartis' (NVS) generics unit, Sandoz, inks deal with Polpharma Biologics for a proposed natalizumab biosimilar for the treatment of RRMS.
Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies
by Zacks Equity Research
Novartis (NVS) MS drug meets primary and secondary endpoints in late-stage studies.
Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo
by Zacks Equity Research
Ionis (IONS) out-licenses antisense medicines to Glaxo for treating chronic hepatitis B virus infection. Glaxo exercises its option to in-license the same. Shares fall.
5 ROE Stocks to Profit as Trade War Flip-Flops Rattle Market
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA
by Zacks Equity Research
AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.
Amgen (AMGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Investors Undervaluing Biogen (BIIB) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Mergers & Acquisitions Take Center Stage in Biotech Industry
by Zacks Equity Research
Mergers & acquisitions are in focus in the biotech industry as it undergoes a wave of consolidation.
5 ROE Stocks to Profit as Trade War Spurs Volatility
by Supriyo Bose
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
Top Ranked Momentum Stocks to Buy for August 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 12th.
PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.
Intercept (ICPT) Q2 Earnings & Sales Beat, NASH in Focus
by Zacks Equity Research
Intercept (ICPT) posts a narrower-than-expected loss in Q2 and surpasses sales estimates.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Biotech ETFs in Focus on Impressive Q2 Earnings Results
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.
Top Ranked Momentum Stocks to Buy for August 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 2nd.